Get the Stockscreener App
0.00
100.00%
-27.73
Galapagos Nv Adr stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
See More
Previous Close:
$27.73
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$1.83B
Revenue:
$1.28B
Net Income/Loss:
$391.32M
P/E Ratio:
0.00
EPS:
5.9613
Net Cash Flow:
$-238.89M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$37.78
Galapagos Nv Adr Stock (GLPG) Company Profile
Compare GLPG vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLPG
Galapagos Nv Adr
|
0.00 | 1.83B | 1.28B | 391.32M | -238.89M | 5.9613 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galapagos Nv Adr Stock (GLPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-22-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Aug-05-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Feb-14-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-24 | Downgrade | Kepler | Hold → Reduce |
| Sep-09-24 | Initiated | Leerink Partners | Market Perform |
| Aug-02-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-28-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-24-23 | Downgrade | Citigroup | Buy → Neutral |
| May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-23 | Upgrade | Jefferies | Underperform → Hold |
| Nov-07-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-27-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-19-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-06-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-20-21 | Initiated | Deutsche Bank | Buy |
| Apr-14-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-23-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Feb-19-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-19-20 | Initiated | Maxim Group | Buy |
| Oct-21-20 | Downgrade | Goldman | Neutral → Sell |
| Aug-25-20 | Downgrade | Jefferies | Buy → Hold |
| Aug-24-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-19-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-19-20 | Upgrade | Citigroup | Neutral → Buy |
| Jul-10-20 | Downgrade | Stifel | Buy → Hold |
| Mar-30-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-20 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-25-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-24-20 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Jan-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-18-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-17-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Dec-02-19 | Initiated | BofA/Merrill | Neutral |
| Sep-09-19 | Resumed | Morgan Stanley | Overweight |
| Jul-31-19 | Upgrade | UBS | Neutral → Buy |
| Jul-29-19 | Downgrade | Jefferies | Buy → Hold |
View All
Galapagos Nv Adr Stock (GLPG) Latest News
Why Is Galapagos N.V. Sponsored ADR (LKFT) Stock Up Today? - Meyka
Why Is Galapagos N.V. Sponsored ADR (LKFT) Stock Down Today? - Meyka
Galapagos N.V. Sponsored ADR (LKFT) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
LKFT Stock Price, Quote & Chart | LAKEFRONT BIOTHERAPEUTIC-ADR (NASDAQ:LKFT) - ChartMill
GLPG SEC FilingsGalapagos Nv 10-K, 10-Q, 8-K Forms - Stock Titan
Earnings call transcript: Galapagos NV sees 91% revenue drop in Q1 2026 - Investing.com
Earnings call transcript: Galapagos NV sees 91% revenue drop in Q1 2026 By Investing.com - Investing.com South Africa
Galapagos NV Sponsored ADR (LKFT) Stock Live Price, Chart & News - CoinCodex
Lakefront Biotherapeutics (NASDAQ: GLPG) outlines ADR deposit terms - Stock Titan
LKFT Stock Price and Chart — NASDAQ:LKFT - TradingView
LKFT Stock Price and Chart — EURONEXT:LKFT - TradingView
Galapagos Q1 2026 presentation: Ouro deal, rebranding highlight transformation By Investing.com - Investing.com South Africa
Earnings call transcript: Galapagos Q1 2026 beats EPS, revenue falls short By Investing.com - Investing.com South Africa
Earnings call transcript: Galapagos Q1 2026 beats EPS, revenue falls short - Investing.com
Galapagos Q1 2026 presentation: Ouro deal, rebranding highlight transformation - Investing.com
Galapagos (GLPG) posts Q1 2026 profit and commits up to €790M to Ouro deal - Stock Titan
GLPG.AS Stock Price, Quote & Chart | GALAPAGOS NV (AMS:GLPG) - ChartMill
GLPG Stock Price, Quote & Chart | GALAPAGOS NV-SPON ADR (NASDAQ:GLPG) - ChartMill
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - Benzinga
Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition - Sahm
ETFs Investing in Galapagos NV Sponsored ADR Stocks - TradingView
Galapagos FY 2025 slides: €3B cash fuels transformation strategy - Investing.com Australia
RBC Capital raises Galapagos stock price target to $33 on model updates - Investing.com South Africa
Earnings call transcript: Galapagos Q4 2025 earnings surpass expectations, stock rises By Investing.com - Investing.com South Africa
Galapagos stock rating reiterated at Market Perform by Raymond James - Investing.com
Galapagos FY 2025 slides: €3B cash fuels transformation strategy By Investing.com - Investing.com South Africa
Earnings call transcript: Galapagos Q4 2025 earnings surpass expectations, stock rises - Investing.com
Earnings Breakdown: Galapagos Q4 - Sahm
A Peek at Galapagos's Future Earnings - Sahm
Stock Market Today: Nasdaq Futures Pare Losses, Dow Drops After Scaling Record Highs— CoreWeave, Vistra, Microchip Technology In Focus (UPDATED) - Benzinga
Stock Market Today: Dow Jones Futures Drop After Scaling Record Highs— CoreWeave, Vistra, Microchip Technology In Focus - Sahm
AngioDynamics, Microchip Technology And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Galapagos stock holds steady as Raymond James maintains Market Perform rating - Investing.com
Bernstein initiates Market Perform rating on Galapagos stock with EUR27.90 target - Investing.com
Earnings call transcript: Galapagos Q3 2025 sees earnings miss, stock steady - Investing.com
Galapagos stock price target raised to $28 from $27 at RBC Capital - Investing.com
PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks - Benzinga
Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), Pharvaris (PHVS) and Stevanato Group (STVN) - The Globe and Mail
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real? - TechStock²
Galapagos NV (GLPG)' CAR-T Therapy Hits 97% Response Rate in Lymphoma Trial - Finviz
Raymond James reiterates Market Perform rating on Galapagos stock - Investing.com
GLPG Stock Price, News & Analysis - Stock Titan
Galapagos To Spin Off Innovative Medicines Business - Forbes
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies By Investing.com - Investing.com UK
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
ProShares Ultra Nasdaq Biotechnology Holdings - Quiver Quantitative
Leerink Partners gives Market Perform rating to Galapagos NV stock, flags R&D challenges - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Billionaire hedge fund manager David Einhorn’s portfolio revealed - Daily Investor
What is the current Price Target and Forecast for Galapagos (GLPG) - Zacks Investment Research
BeiGene Ltd. (BGNE) Share Price, Stock Analysis, Annual Report - Value Research
Galapagos Nv Adr Stock (GLPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):